COLY-MYCIN S (colistin sulfate) by Pfizer is clinical pharmacology colistin sulfate is a polypeptide antibiotic which penetrates into and disrupts the bacterial cell membrane. Approved for superficial bacterial infections of the external auditory canal, caused by organisms susceptible to the action of the antibiotics.
Drug data last refreshed 2h ago · AI intelligence enriched 2w ago
COLY-MYCIN S is a fixed-combination otic suspension containing colistin sulfate, neomycin sulfate, hydrocortisone acetate, and thonzonium bromide. It treats superficial bacterial infections of the external auditory canal caused by susceptible organisms including Staphylococcus aureus, Pseudomonas aeruginosa, and Escherichia coli. The formulation works through dual bactericidal mechanisms: colistin disrupts bacterial cell membranes while neomycin inhibits protein synthesis, combined with anti-inflammatory and tissue-penetrating agents.
Pre-launch stage with established competitor dominance by Cortisporin; brand team will focus on differentiation and market penetration in a mature, competitive segment.
CLINICAL PHARMACOLOGY Colistin sulfate is a polypeptide antibiotic which penetrates into and disrupts the bacterial cell membrane. Neomycin sulfate is an aminoglycoside antibiotic which inhibits protein synthesis, disrupting the normal cycle of ribosomal function. Hydrocortisone acetate is a…
Worked on COLY-MYCIN S at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Joining COLY-MYCIN S at launch offers exposure to commercial execution, competitive positioning, and market penetration in a mature therapeutic category. Career growth depends on driving market share against entrenched competitors and capitalizing on potential Cortisporin LOE transitions, with primary focus on sales force enablement and market access rather than clinical innovation.